Bausch Health Companies

11:06 AM EST - Bausch Health Companies : Said its Bausch + Lomb subsidiary today announced that on December 27, 2018, Health Canada issued the Notice of Compliance (NOC) for VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%). VYZULTA™, the first prostaglandin analog with one of its metabolites being Nitric Oxide (NO), is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.i VYZULTA™ is the first new innovative treatment for open-angle glaucoma in Canada in almost twenty years. Bausch Health Companies shares T.BHC are trading up $1.23 at $28.88.